Zealand Pharma teams with Generate Biomedicines on AI‑driven protein therapeutics
+1 new source since this summary was written
Zealand Pharma announced a collaboration with Generate Biomedicines to create protein‑based drugs for obesity and metabolic disorders using generative AI. Generate will be paid $30 million up front and can earn up to $35 million in early pre‑clinical milestones for two initial programs, with the chance to receive nearly $1.2 billion in later milestones and royalties. The partnership assigns Generate the early research and candidate selection, while Zealand will manage clinical development, regulatory filings and worldwide commercialization.
Why it matters
The deal gives Zealand access to AI‑designed protein candidates, potentially expanding its pipeline and revenue streams. Investors may see future milestone payments and royalty income if the programs advance, as noted in the press release.
Key facts
- 1Generate will receive $30 million upfront under the agreement. investing.com
- 2Generate can earn up to $35 million in early pre‑clinical milestones for two initial programs. investing.com
- 3Total milestone payments could reach nearly $1.2 billion, plus tiered royalties on worldwide net sales of any commercialized products. investing.com
- 4The collaboration starts with two initial programs and includes an option to add a third program. investing.com
- 5Generate will lead research and lead‑candidate selection using its generative AI platform. investing.com
- 6Zealand Pharma will handle subsequent clinical development, regulatory submissions and worldwide commercialization. investing.com
Summary written by AlphAI AI Desk from 2 of 2 sources. Not investment advice. Figures are as stated by the linked sources.